{"name":"TARGET","title":"","children":[{"id":"ASCT2","name":"ASCT2","presenterLast":"ASCT2","children":[{"id":10662,"name":10662,"title":"Discovery and development of MEDI7247, a novel Pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological and solid cancers","presenterFirst":"Nabendu","presenterLast":"Pore","keywords":"Pyrrolobenzodiazepines;Antibody;Solid tumors;Multiple myeloma","target":"ASCT2","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":10703,"name":10703,"title":"MEDI7247: A first in class antibody drug conjugate targeting ASCT2 in a range of solid tumors","presenterFirst":"Kevin","presenterLast":"Schifferli","keywords":"Targeted drug delivery;Antibody;Solid tumors;Pyrrolobenzodiazepines","target":"ASCT2","tumor":"lung_colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CAIX","name":"CAIX","presenterLast":"CAIX","children":[{"id":3971,"name":3971,"title":"Head-to-head comparison of ADC and SMDC products, alone and in combination with antibody-IL2 fusion proteins","presenterFirst":"Samuele","presenterLast":"Cazzamalli","keywords":"Combination studies;Tumor Targeting;Targeted Cytotoxics;Immunocytokines","target":"CAIX","tumor":"renal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CD33","name":"CD33","presenterLast":"CD33","children":[{"id":5865,"name":5865,"title":"Synergistic antileukemic activity of the antibody-drug conjugate (IMGN779) combined with PARP inhibition in preclinical human acute myeloid leukemia models","presenterFirst":"Eunice","presenterLast":"Wang","keywords":"PARP;Antibody;Leukemias: acute myeloid;DNA damage response","target":"CD33","tumor":"leukemia","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical in vitro"}]},{"id":"CD48","name":"CD48","presenterLast":"CD48","children":[{"id":886,"name":886,"title":"Additional mechanisms of action of SGN-CD48A in multiple myeloma and improved antitumor activity in combination with daratumumab","presenterFirst":"Timothy","presenterLast":"Lewis","keywords":"Antibody;Drug delivery;Microtubule-interfering agents;Multiple myeloma","target":"CD48","tumor":"myeloma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CD79b","name":"CD79b","presenterLast":"CD79b","children":[{"id":3562,"name":3562,"title":"Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1","presenterFirst":"Dhara","presenterLast":"Amin","keywords":"Bcl-2 protein family;venetoclax;Lymphoma: non-Hodgkin's lymphoma;antibody drug conjugates","target":"CD79b","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"HER2","name":"HER2","presenterLast":"HER2","children":[{"id":5975,"name":5975,"title":"Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells","presenterFirst":"Wan-Chen","presenterLast":"Wei","keywords":"Breast cancer;HER-2;Metformin;T-DM1","target":"HER2","tumor":"breast","sage":"resistance","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":10616,"name":10616,"title":"Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2","presenterFirst":"Tary","presenterLast":"Traore","keywords":"HER-2;Cancer immunotherapy;Checkpoint;XMT-1522","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":10689,"name":10689,"title":"HER2-targeted antibody drug conjugates induce host immunity and target cancer stem cells and the efficacy can be enhanced by anti-PD-L1","presenterFirst":"Qiao","presenterLast":"Li","keywords":"Cancer stem cell;antibody drug conjugate;anti-PD-L1;TILs","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"HSP90","name":"HSP90","presenterLast":"HSP90","children":[{"id":6760,"name":6760,"title":"Combination of the miniature drug conjugate PEN-866 with PARP inhibitors as a rational approach to overcoming limitations of PARP inhibitor monotherapy","presenterFirst":"Samantha","presenterLast":"Perino","keywords":"PARP;Combination studies;topoisomerase I inhibitor","target":"HSP90","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]}]}
